Jennewein Biotechnologie GmbH’s Conclusion That Its 2’-Fucosyllactose Is GRAS For Use In Infant Formula And Toddler Nutrition Is Accepted By U.S. FDA

RHEINBREITBACH, Germany--(BUSINESS WIRE)--Jennewein Biotechnologie GmbH, today announces that it has received acknowledgement from the U.S. Food and Drug Administration (“FDA”) that it has no questions at this time regarding Jennewein’s conclusion that its biotechnological produced human milk oligosaccharide (HMO) 2’-Fucosyllactose is generally recognized as safe (“GRAS”) for use in Infant and Toddler nutrition. FDA based its notification (GRN 571) on information provided by Jennewein Biotechnologie as well as other information available to the FDA. Jennewein 2’-Fucosyllactose represents the very first HMO being produced by a bacterial fermentation process and entering the market in the US.

Back to news